Precision oncology's translation gap-Can molecular tumor boards bridge it?
Where this comes from
- Record sourced from PubMed, PMID 42378308.
- Also identified by DOI 10.1371/journal.pmed.1005165.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Precision oncology is revolutionizing cancer care, but isn't reaching enough patients. Molecular tumor boards (MTBs) translate complex genomic data to more effectively inform personalized care, and a new meta-analysis shows they boost clinical outcomes. But how can we feasibly and equitably expand the use of MTBs?
Medical subject headings
- Precision Medicine
- Neoplasms
- Medical Oncology
- Translational Research, Biomedical